Please provide your email address to receive an email when new articles are posted on . Omeros Corp. announced that the U.S. Food and Drug Administration has approved the use of phenylephrine and ...

Omeros reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. This multicenter, double-blind, ...

Lake Oswego, OR - January 08, 2026 - PRESSADVANTAGE - At Tersigni Vision, a growing number of patients are asking ...

-- Submission of New Drug Application Planned for First Half of 2013-- -- Company to Host Conference Call Today at 9:00 a.m. EST-- SEATTLE, Nov. 5, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: ...

SEATTLE, June 2, 2014--Omeros Corporation OMER +8.64% today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use ...

SEATTLE, Jan. 22, 2013 /PRNewswire/ – Omeros Corporation (OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical ...

(Reuters Health) - Seniors who get new lenses implanted during cataract surgery may not only see better but also experience better sleep, suggests a new study of how light entering the eye regulates ...

Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.

Omeros reported positive data from its Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302 met its primary endpoint by demonstrating ...

The US Food and Drug Administration (FDA) has approved phenylephrine and ketorolac injection (Omidria, Omeros Corporation) 1%/3% for use during cataract surgery or intraocular lens replacement (ILR), ...